Cargando…

MicroRNA-155-5p, Reduced by Curcumin-Re-Expressed Hypermethylated BRCA1, Is a Molecular Biomarker for Cancer Risk in BRCA1-methylation Carriers

Constitutional BRCA1-methylation is a cancer risk factor for breast (BC) and ovarian (OC) cancer. MiR-155, regulated by BRCA1, is a multifunctional microRNA that plays a crucial role in the immune system. The present study assessed the modulation of miR-155-5p expression in peripheral white blood ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Moghrabi, Nisreen, Al-Showimi, Maram, Al-Yousef, Nujoud, AlOtai, Lamya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219443/ https://www.ncbi.nlm.nih.gov/pubmed/37240365 http://dx.doi.org/10.3390/ijms24109021

Ejemplares similares

Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines
por: Al-Yousef, Nujoud, et al.
Publicado: (2020)

MicroRNA-126 expression in the peripheral white blood cells of patients with breast and ovarian cancer is a potential biomarker for the early prediction of cancer risk in the carriers of methylated BRCA1
por: Al-Showimi, Maram, et al.
Publicado: (2022)

Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters
por: Al-Moghrabi, Nisreen, et al.
Publicado: (2018)

The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females
por: Al-Moghrabi, Nisreen, et al.
Publicado: (2014)

BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer
por: Al-Moghrabi, Nisreen M.
Publicado: (2017)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

Prostate screening uptake in Australian BRCA1 and BRCA2 carriers
por: McKinley, Joanne M, et al.
Publicado: (2007)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation
por: de Jong, Vincent M. T., et al.
Publicado: (2022)

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction
por: Tai, Yu Chuan, et al.
Publicado: (2008)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1
por: Chang, Suhwan, et al.
Publicado: (2012)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
por: Depypere, Herman, et al.
Publicado: (2021)

Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
por: Silvestri, Valentina, et al.
Publicado: (2016)

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
por: Prieske, Katharina, et al.
Publicado: (2017)

The role of BRCA1/2 in hereditary and familial breast and ovarian cancers
por: Hawsawi, Yousef M., et al.
Publicado: (2019)

Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2005)

Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up
por: Ponder, B
Publicado: (2000)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy
por: Schmidt, MK, et al.
Publicado: (2005)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
por: McCrorie, Alan D, et al.
Publicado: (2020)

Correction: Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives
por: Nilsson, Martin P., et al.
Publicado: (2017)

HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers
por: van der Groep, Petra, et al.
Publicado: (2013)

Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m92ht93kr6d5tr7kqh5p3gjbdo